Ashland is in the middle of a credibility rebuild. Fiscal Q3 2026 - the three months ended June 30, 2026 - produced $497 million in sales, up 7% year over year, and operating income of $43 million, a sharp swing from a $708 million operating loss in the prior-year quarter that was dominated by a $706 million non-cash goodwill impairment. Underneath that headline, the business looks healthier than it has in several quarters: gross margin expanded to 34.2% from 28.5%, year-to-date operating cash flow from continuing operations tripled to $295 million from $94 million, and management reaffirmed full-year sales guidance of $1,835 to $1,870 million alongside Adjusted EBITDA guidance of $385 to $400 million.
The story for investors is not the size of the rebound but its composition. Life Sciences posted 11% sales growth in the quarter and Personal Care held flat-to-positive, while Specialty Additives - the segment that took the largest goodwill writedown a year ago - finally showed real operating improvement with $18 million of segment EBITDA versus a $309 million loss in the year-ago quarter. Adjusted EPS guidance was nudged down to "low-to-mid single digit growth" from "mid-to-high single digit" because of a higher tax rate, but the operating trajectory is intact. The bigger qualitative questions - legacy asbestos exposure, the early-2026 ratings downgrades to BB/Ba2, and the heavy fiscal 2028 debt maturity wall - are real but increasingly well-catalogued in the numbers. Net cash, a 2.3x net leverage covenant ratio, and a $520 million repurchase authorization give management flexibility to play both offense (pricing actions in additives, share repurchases) and defense (asbestos reserve adjustments) without straining the balance sheet.
The result is a specialty chemicals name that has cleaned up its balance sheet, pruned non-core assets, and is generating real free cash - but trades at a discount to large diversified peers because of the asbestos liability overhang, the BB-rated credit profile, and uncertainty about the durability of the post-impairment earnings base. The risk-reward has improved meaningfully from a year ago, and the September 2028 maturity tower of $571 million is the single most important number to watch over the next 18 months.